AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03834688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days).
Study NCT03834688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.
Study NCT03834688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
Study NCT01684423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
Study NCT01684423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
Study NCT04265625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic guidance
Description: Percutaneous tracheotomy performed by endoscopic guidance
Study NCT01708954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01708954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01708954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03674138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DNA-guided choice of therapy
Description: Buccal swab for DNA genotyping to identify best antidepressant therapy
Study NCT03674138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical management
Description: Clinical management to identify best antidepressant therapy
Study NCT02854683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 1 liter of intravenous saline will be delivered over 1 hour
Study NCT02854683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution
Description: 1 liter of ORS solution given by mouth
Study NCT00101972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody RAV12
Description: Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
Study NCT01975090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY IVC Filter
Description: The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
Study NCT02685605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery
Study NCT02685605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgery
Study NCT02685605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
Study NCT02685605 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: EBRT to 60 Gy plus 75 mg/m2/d temozolomide
Study NCT02685605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: EBRT to 60 Gy plus 75 mg/m2/d temozolomide
Study NCT02685605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
Study NCT02685605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
Study NCT03467412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: intradermal injection
Study NCT03467412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradermal injection
Study NCT03179982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe South Africa
Description: Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills
Study NCT06287697 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02116686 — intervention group
Intervention type: DEVICE
Intervention: ventilatory polygraphic recordings
Description: Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
Study NCT00896285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large bore chest drain + NSAID based analgesic regimen
Description: Chest tube greater than 14 French size and ibuprofen.
Study NCT00896285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small bore chest drain + NSAID based analgesic regimen
Description: Chest tube less than or equal to 14 French size and ibuprofen.
Study NCT00896285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large bore chest drain + opiate based analgesic regimen
Description: Chest tube greater than 14 French size and morphine.
Study NCT00896285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small bore chest drain + opiate based analgesic regimen
Description: Chest tube less than or equal to 14 French size and morphine.
Study NCT03216330 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
Study NCT03040076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Treatment
Description: Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
Study NCT03040076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Condition
Description: Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
Study NCT05852782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light therapy
Description: Participants will be exposed to broadband light for one hour
Study NCT01684423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939) suspension
Description: Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
Study NCT03924180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement for PKU patients
Description: For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
Study NCT03924180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement for PKU patients
Description: For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
Study NCT02148978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
Study NCT03411499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery
Description: Surgery within 72 hours from endocarditis diagnosis
Study NCT03411499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Delayed surgical intervention or medical treatment according to the current guidelines
Study NCT03379766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Successor of Phonak Audéo B-Direct
Description: The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
Study NCT03379766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo B-Direct
Description: The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
Study NCT02008695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: adult microfinance
Description: Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households
Study NCT02008695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth microfinance only
Description: One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
Study NCT02008695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: youth and adult micro finance
Description: One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
Study NCT01419392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 25 mg orally, 4 times per day for 21 days
Study NCT01419392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: orally, 4 times per day for 21 days
Study NCT02079350 — intervention group
Intervention type: DRUG
Intervention: %6 HES and %4 Gelofusine
Study NCT04027530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
Study NCT04027530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ertugliflozin 15 mg
Description: Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
Study NCT00905983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Docetaxel
Description: Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
Study NCT04275739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Episodic Future Thinking
Description: Brief Academic goal related EFT intervention involving desirable outcomes of current academic goals
Study NCT04275739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivid Memory Task
Description: Matched for time control task involving recall of vivid memories of distinct events/actions from a children's story
Study NCT04111120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
Description: Coagulation assessment using heparinase treated SONOCLOT
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX320
Description: IDX320 400 mg in tablets (8x50 mg) administered orally once daily
Study NCT05852782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light therapy
Description: Participants will be exposed to blue light for one hour
Study NCT05852782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red light therapy
Description: Participants will be exposed to re light for one hour
Study NCT05852782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Darkness
Description: Participants will be in complete darkness for one hour
Study NCT03126188 — intervention group
Intervention type: DRUG
Intervention: Venlafaxine
Description: Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
Study NCT01870999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole IM depot
Description: Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
Study NCT00910858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5-mg capsules for oral administration
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: IDX184 100 mg in capsules (2x50 mg) administered orally once daily
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184 placebo
Description: IDX184 matching placebo in capsules administered orally once daily
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDX184 placebo
Description: IDX184 matching placebo in capsules administered orally once daily
Study NCT01870999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole tablets
Description: Aripiprazole tablets 10 mg once daily in the morning for 14 days.
Study NCT01522976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT01522976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01522976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01522976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT00146835 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pediarix
Description: 1 or more injections
Study NCT00146835 — intervention group
Intervention type: BIOLOGICAL
Intervention: Licensed DTPa containing vaccine
Description: 1 or more injections
Study NCT00146835 — intervention group
Intervention type: BIOLOGICAL
Intervention: Prevnar®: (Wyeth)
Description: Concomitant vaccination
Study NCT04126226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech-language guidance
Description: Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
Study NCT04126226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy exercises for swallowing
Description: Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
Study NCT04126226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy exercises for speech
Description: Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
Study NCT04139395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Citrate PET/MRI
Description: Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
Study NCT04139395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67Ga-Citrate SPECT
Description: 67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
Study NCT04139395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Imaging with 68Ga-Citrate PET/MRI
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX320 placebo
Description: IDX320 matching placebo in tablets administered orally once daily
Study NCT01157104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDX320 placebo
Description: IDX320 matching placebo in tablets administered orally once daily
Study NCT02073929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide for 26 weeks
Description: GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
Study NCT02073929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo s.c. daily for 26 weeks
Study NCT04139395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Imaging with 68Ga-Citrate PET/MRI
Study NCT02807038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
Study NCT03768908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
Study NCT03768908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate + Amodiaquine
Description: Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
Study NCT01019759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
Study NCT03390972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (NaCl 0.9%) TCI infusion
Study NCT03390972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
Study NCT01489436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port cholecystectomy
Description: In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
Study NCT01489436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Description: The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
Study NCT02719717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Ace+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
Study NCT04139395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT
Description: Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
Study NCT04653103 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Biopsy of the liver to assess for Non-alcoholic steatohepatitis